Anti-EGFR Antibody-drug Conjugate CPO301

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-EGFR ADC CPO301, the monoclonal antibody moiety binds to EGFR on tumor cell surfaces. Upon binding and internalization, the cytotoxic agent is released and kills the EGFR-expressing cancer cells, through an as of yet unknown mechanism of action. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.

**Synonyms:** - Anti-EGFR ADC CPO301 - Anti-EGFR Antibody-drug Conjugate SYS6010 - CPO 301 - CPO-301 - CPO301 - SYS 6010 - SYS-6010 - SYS6010